Cain Dimon, MD
Pain Medicine · Royal Oak, MINPI 1437196839
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Nevro Corp. at 36.5% of the total. Reporting peaked in 2022 at $1,383 and has fallen 88.6% since, to $158 in 2025.
Across 49 payments — averaging $76.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$1K
- Medtronic$1K
- SPR Therapeutics, Inc$344
- Boston Scientific$336
- Abbott$226
- Saluda Medical Americas, Inc.$101
- plus $91 from 1 others
What the payments were for
- Food & beverage$3,734100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 19 | $1,363 |
| Medtronic | 17 | $1,274 |
| SPR Therapeutics, Inc | 3 | $344 |
| Boston Scientific | 4 | $336 |
| Abbott | 4 | $226 |
| Saluda Medical Americas, Inc. | 1 | $101 |
| GRT US Holding, Inc. | 1 | $91 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnia$864
- INTELLIS$509
- INTELLIS ADAPTIVESTIM$397
- Senza$270
- SPRINT PNS System$260
- GENERAL PAIN MANAGEMENT$132
- PROCLAIM$117
- GENERAL - THERAPIES$111
- Evoke SCS$101
How this compares
$3,734 in reported general payments places this provider in the 60th percentile of 139 pain medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 21 | $11,162 |
| ButransBuprenorphine | 15 | $5,287 |
| Oxycodone Hcl | 166 | $3,831 |
| Hydromorphone ErHydromorphone Hcl | 11 | $2,555 |
| Lidocaine | 29 | $2,473 |
| Gabapentin | 111 | $2,384 |
| Pregabalin | 102 | $2,276 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 62 | $2,103 |
| Hydromorphone Hcl | 65 | $1,861 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 48 | $1,602 |
| Fentanyl | 19 | $1,564 |
| Duloxetine Hcl | 80 | $1,093 |
| Tizanidine Hcl | 81 | $961 |
| Naloxone Hcl | 12 | $802 |
| Morphine Sulfate ErMorphine Sulfate | 26 | $731 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Royal Oak
- Craig HartrickRoyal Oak$26K
- Daniel SapeikaRoyal Oak$8K
- Harry SukumaranRochester Hills$304K
- Nasir KhatriFlint$133K
- Yijia ChuGrand Rapids$88K
- Mark MounayerSouthfield$85K
- Jeffrey RosenbergCanton$44K
- Alexander TurfeWyandotte$41K
- Kendall GroseWyandotte$26K
- Patrick ForrestAnn Arbor$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.